You are here

Methods Study to Evaluate Use of Cardiac Ultrasound to Assess Heart Valve Abnormality in People.

Last updated on November 13, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
New Haven, Connecticut, 06511-5473 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Heart Valve Diseases
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- >=18 years of age subjects with stable concomitant diseases with BMI >=30 kg/m2

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Pregnant females

- Those with unstable/new onset diseases

- Those who are on agents known to be associated with cardiac valvular heart disease

NCT00359489
Pfizer
Completed
Methods Study to Evaluate Use of Cardiac Ultrasound to Assess Heart Valve Abnormality in People.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Descriptive Information
Brief TitleMethods Study to Evaluate Use of Cardiac Ultrasound to Assess Heart Valve Abnormality in People.
Official TitleA Randomized, Open-Label, Methodology Trial To Investigate The Utility Of Echocardiography In Assessment Of Cardiac Valvular Regurgitation In Adult Subjects
Brief SummaryMethods study to evaluate use of cardiac ultrasound to assess heart valve abnormality in people.
Detailed DescriptionNot Provided
Study TypeObservational
Study DesignObservational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Target Follow-Up DurationNot Provided
BiospecimenNot Provided
Sampling MethodNot Provided
Study PopulationNot Provided
ConditionHeart Valve Diseases
InterventionDevice: cardiac echosonography
Study Groups/CohortsNot Provided
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment StatusCompleted
Enrollment
 (submitted: July 31, 2006)
30
Original EnrollmentSame as current
Actual Study Completion DateJuly 2007
Primary Completion DateNot Provided
Eligibility Criteria

Inclusion Criteria:

  • >=18 years of age subjects with stable concomitant diseases with BMI >=30 kg/m2

Exclusion Criteria:

  • Pregnant females
  • Those with unstable/new onset diseases
  • Those who are on agents known to be associated with cardiac valvular heart disease
Sex/Gender
Sexes Eligible for Study:All
Ages18 Years and older   (Adult, Older Adult)
Accepts Healthy VolunteersYes
ContactsContact information is only displayed when the study is recruiting subjects
Listed Location CountriesUnited States
Removed Location Countries  
 
Administrative Information
NCT NumberNCT00359489
Other Study ID NumbersA9001336
Has Data Monitoring CommitteeNot Provided
U.S. FDA-regulated ProductNot Provided
IPD Sharing StatementNot Provided
Responsible PartyNot Provided
Study SponsorPfizer
CollaboratorsNot Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateSeptember 2007

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now